

## Ovarian cancer: identifying and managing familial and genetic risk

### Guideline committee interests register

Register last updated: February 2023

All interests have been signed off by the Chair and the NICE Developer Lead, except where otherwise stated

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Victoria Barber	Committee member	Direct financial interest	GP at Parklands Surgery, Rushden, NN10 9EB	1998	24/10/2022	Ongoing	Non-specific. Member's paid employment. Declare and participate. Rationale: Salaried employment in the NHS. This interest is non-specific.
Dr Victoria Barber	Committee member	Direct non-financial professional and personal interest	GP Ambassador for Target Ovarian Cancer	2011	06/01/2022	Ongoing	Specific. Declare and participate. Rationale: This is a direct interest but there is no financial benefit from this role.
Dr Victoria Barber	Committee member	Direct non-financial professional and personal interest	I give talks on ovarian cancer to GP and HCP groups along with lay women's groups. I have given evidence to All Parliamentary Groups, lobbied for better access to ovarian cancer tests, am a member of focus groups within Target. I do not receive financial reward for these.	Pre-January 2022	06/01/2022	Ongoing	Specific. Declare and participate. Rationale: This is a direct interest but there is no financial benefit from this role.
Dr Victoria Barber	Committee member	Direct non-financial professional	Involved in preliminary discussions regarding Target Ovarian Cancer pathfinder study	April 2022	29/12/2022	October 2022	Specific. Declare and participate.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
		and personal interest					Rationale: Whilst this study is relevant to the information and support topic of the guideline, it was not included as evidence. The committee member's involvement in the study was also preliminary rather than being involved as a main author.
Dr Rebecca Bowen	Committee member	Direct financial interest	Consultant Medical Oncologist Royal United Hospitals Bath NHS Foundation Trust	2011	13/11/2022	Ongoing	Non-specific. Member's paid employment. Declare and participate. Rationale: Salaried employment in the NHS.
Dr Rebecca Bowen	Committee member	Direct financial interest	Private Medical Practice – BMI Bath Clinic – delivering anti-cancer treatment for breast and gynaecological cancers (4 hours a week would not see women who have not already been identified as having a risk of ovarian cancer)	2012	27/11/2021	Ongoing	Non-specific. Declare and participate. Rationale: This is a financial interest related to salaried sessional employment in private healthcare but it is non-specific to the scope of the guideline.
Dr Rebecca Bowen	Committee member	Direct financial interest	Payments for speaking engagements at educational events and advisory boards: GSK, Clovis, AstraZeneca.  Pharmacological ovarian cancer treatment, tumour testing.	2012	27/11/2021	Ongoing	Non-specific. Declare and participate. Rationale: This is a financial interest but it is non-specific to the scope of the guideline.
Dr Rebecca Bowen	Committee member	Direct financial interest	Speaker at sponsored meetings – GSK, AZ, Clovis, Esai, Bessins, Roche	2016	13/11/2022	Ongoing	Non-specific. Declare and participate.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
							Rationale: This is a financial interest but it is non-specific to the scope of the guideline because pharmacological treatment of ovarian cancer is outside the scope of this guideline.
Dr Rebecca Bowen	Committee member	Direct non-financial professional and person interest	Breast Cancer UK: Scientific adviser	2015	27/11/2021	Ongoing	Non-specific. Declare and participate. Rationale: This is a financial interest but it is non-specific to the scope of the guideline.
Dr Rebecca Bowen	Committee member	Direct non-financial professional and person interest	NCRI Ovarian Work Stream Lead	2020	27/11/2021	Ongoing	Specific. Declare and participate. Rationale: As part of this role decisions are made collaboratively by consensus and there is no financial gain.
Dr Rebecca Bowen	Committee member	Direct non-financial professional and person interest	British Gynaecological Cancer Society (BGCS) Medical Oncology Representative	2019	27/11/2021	July 2022	Specific. Declare and participate. Rationale: As part of this role decisions are made collaboratively by consensus and there is no financial gain.
Dr Rebecca Bowen	Committee member	Direct non-financial professional and person interest	Co-chair UKGOM	April 2018	07/02/2022	Ongoing	Specific. Declare and participate. Rationale: As part of this role decisions are made collaboratively by consensus and there is no financial gain.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Rebecca Bowen	Committee member	Direct non-financial professional and person interest	NCRI Gynae exec committee	2016	07/02/2022	Ongoing	Specific. Declare and participate. Rationale: As part of this role decisions are made collaboratively by consensus and there is no financial gain.
Dr Rebecca Bowen	Committee member	Direct non-financial professional and person interest	Newson Health Menopause Society Advisory Board	2021	07/02/2022	March 2023	Specific. Declare and participate. Rationale: This is an advisory role and there is no financial gain.
Dr Rebecca Bowen	Committee member	Direct non-financial professional and person interest	Invited to join the NICE Quality Standards Advisory Committee as specialist member to develop the update to the NICE ovarian cancer quality standard	November 2023	14/11/2023	Ongoing	Specific. Declare and participate. Rationale: No further recommendations are being developed and therefore participation in the Quality Standard does not impact on this guideline.
Dr Adam Brentnall	Committee member	Direct financial interest	Senior Lecturer employed by Queen Mary University of London	March 2009	24/10/2022	Ongoing	Non-specific. Member's paid employment. Declare and participate. Rationale: Salaried employment in higher education (Queen Mary University of London).
Dr Adam Brentnall	Committee member	Direct financial interest	I receive royalties from Cancer Research UK arising from commercial use of the Tyrer-Cuzick (or IBIS) breast cancer risk algorithm	2014	14/02/2022	Ongoing	Non-specific. Declare and participate.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
							Rationale: This is non-specific to ovarian cancer.
Dr Adam Brentnall	Committee member	Direct non-financial professional and person interest	<p>I have been involved in statistical aspects of research studies investigating the effectiveness of gene testing for breast and ovarian cancer prevention, including:</p> <p>R. Manchanda, L. Sun, S. Patel, O. Evans, J. Wilschut, A. C. De Freitas Lopes, F. Gaba, A. Brentnall, S. Duffy, B. Cui et al. 'Economic evaluation of population-based BRCA1/BRCA2 mutation testing across multiple countries and health systems'. <i>Cancers</i> 12.7 (2020), p. 1929.</p> <p>L. Sun, A. Brentnall, S. Patel, D. S. Buist, E. J. Bowles, D. G. R. Evans, D. Eccles, J. Hopper, S. Li, M. Southey et al. 'A cost-effectiveness analysis of multigene testing for all patients with breast cancer'. <i>JAMA oncology</i> 5.12 (2019), pp. 1718–1730.</p> <p>As well as research studies investigating the utility of genetic testing for risk of breast cancer (see multiple references on my CV), with relevance.</p>	2011	14/02/2022	Ongoing	<p>Specific.</p> <p>Declare and participate.</p> <p>Rationale: Whilst some of the research papers were included as evidence in some reviews, they were part of a wider evidence base.</p>
Dr Adam Brentnall	Committee member	Direct non-financial professional and personal interest	I am an academic and my career is furthered by publishing.	2006	14/02/2022	Ongoing	<p>Non-specific.</p> <p>Declare and participate.</p> <p>Rationale: This interest is non-specific to the scope of the guideline.</p>

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Adam Brentnall	Committee member	Indirect financial interest	I am PI (or co-PI) on three research projects my institution receives research funding for from: <ul style="list-style-type: none"> <li>• Cancer Research UK</li> <li>• Breast Cancer Now</li> <li>• NIHR</li> </ul>	2019	14/02/2022	2023	Specific. Declare and participate. Rationale: The research funding goes to the University / Unit.
Dr Adam Brentnall	Committee member	Direct non-financial professional and personal interest	I am a member of an expert review panel for Cancer Research UK on Early Detection and Diagnosis Trials, Behavioural, Health Systems and Health Economics Research	2021	14/02/2022	2023	Specific. Declare and participate. Rationale: Funding is allocated based on consensus in accordance with clear criteria. There is no financial gain from this.
Dr Adam Brentnall	Committee member	Direct non-financial professional and personal interest	Xia Wei X; Oxley S; Sideris M; Karla A; Brentnall A; Sun L; Yang L; Legood R; Manchanda R. Quality of life after risk-reducing surgery for breast and ovarian cancer prevention: a systematic review and meta-analysis. 2023	2023	24/03/2023	Ongoing	Specific. Declare and participate. Rationale: This publication was included in evidence report N. This is only one part of a considerable evidence base for this topic and being a co-author is unlikely to unduly influence decision making for this topic.
Dr Adam Brentnall	Committee member	Indirect interest	My institution receives income based on the Research Excellence Framework. Part of the criteria of this is impact beyond academia. Including research from my institution (employer) or department in the NICE guidelines could further the career of individuals within my institution and increase the profile and income of my employer.	2022 if on committee	14/02/2022	Ongoing	Specific. Declare and participate. Rationale: This interest is non-specific to the scope of the guideline.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Adam Brentnall	Committee member	Direct non-financial professional and personal interest	UK National Screening Committee Research and Methodology Group Member	January 2023	01/02/2023	Ongoing	Specific. Declare and participate. Rationale: This interest is non-specific to the scope of the guideline.
Dr Alison Cameron	Chair	Direct financial interest	Consultant Clinical Oncologist, University Hospitals Bristol and Weston NHS Foundation Trust	June 2007	15/11/2022	Ongoing	Specific. Declare and participate. Rationale: Salaried employment in the NHS.
Dr Alison Cameron	Chair	Direct non-financial professional and personal interest	I co-authored a Cochrane review on pegylated liposomal doxorubicin in ovarian cancer in 2013	2013	29/06/2021	2013	Non-specific. Declare and participate. Rationale: This declaration is non-specific to the scope.
Dr D Mark Davies	Committee member	Direct financial interest	Consultant in Medical Oncology, Singleton Hospital, Swansea	June 2014	05/12/2022	Ongoing	Non-specific. Member's paid employment. Declare and participate. Rationale: Salaried employment in the NHS.
Dr D Mark Davies	Committee member	Direct financial interest	Speaker fee (Roche) Talk on comprehensive genomic profiling at regional meeting – general educational	November 2021	20/02/2022	November 2021	Specific. Declare and participate. Rationale: This is a one-time general teaching event and Roche does not produce medication for the primary prevention of ovarian cancer.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr D Mark Davies	Committee member	Direct financial interest	Speaker fee (Novartis) Talk on ESMO update at regional meeting	December 2021	20/02/2022	December 2021	Non-specific. Declare and participate. Rationale: The topic is not specific to the scope of the guideline and Novartis is not involved in producing primary preventive medication for ovarian cancer.
Dr D Mark Davies	Committee member	Direct financial interest	Speaker fee (Lilly) Contribution to educational video on cancer genetics	January 2021	20/02/2022	January 2021	Non-specific. Declare and participate. Rationale: This is a general teaching video which is not making recommendations about risk prevention or risk management and Lilly is not involved in producing primary preventive medication for ovarian cancer.
Dr D Mark Davies	Committee member	Direct financial interest	Consultancy (Pfizer) Consultancy work on the use of value based healthcare (treatment of breast cancer)	January 2021	20/02/2022	Ongoing	Non-specific. Declare and participate. Rationale: The interest is not specific to the purpose of the scope since it is focused on breast rather than ovarian cancer.
Dr D Mark Davies	Committee member	Direct financial interest	Private practice This relates to the treatment of breast cancer. I have not undertaken any private practice during the Covid pandemic and have no immediate plans to do so.	June 2015	20/02/2022	Ongoing	Specific. Declare and participate. Rationale: Very limited private practice.



Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
			Previous private practice has been limited. Generally under one hour a week when averaged out and often several months gaps between private work e.g. one or two private patients a year.				
Professor Melanie Davies	Committee member	Direct financial interest	Consultant Gynaecologist, University College London Hospitals	01/05/1996	24/10/2022	Ongoing	Non-specific. Member's paid employment. Declare and participate. Rationale: Salaried employment in the NHS.
Professor Melanie Davies	Committee member	Direct financial interest	Professor of Reproductive Medicine, University College London (previously Senior Lecturer and Associate Professor)	01/10/2022	24/10/2022	Ongoing	Non-specific. Member's paid employment. Declare and participate. Rationale: Salaried employment in higher education (University College London).
Professor Melanie Davies	Committee member	Direct financial interest	Private practice (2 hours/week)	More than 10 years	13/02/2022	Ongoing	Non-specific. Declare and participate. Rationale: The private practice is not exclusively covering people at increased familial or genetic risk of ovarian cancer.
Professor Melanie Davies	Committee member	Direct non-financial professional and personal interest	Professional organisation: British Menopause Society (BMS). Elected member of medical advisory council	2015	13/02/2022	2021	Non-specific. Declare and participate. Rationale: This is a role related to the general topic of menopause rather than specific to familial or genetic ovarian

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
							cancer. Decisions are made by consensus rather than based on individual member's opinion.
Professor Melanie Davies	Committee member	Direct non-financial professional and personal interest	Professional organisation: BMS / RCOG. Chair, Clinical Studies Group for Post-Reproductive Health	2017	13/02/2022	2020	Non-specific. Declare and participate. Rationale: This is a role related to the general topic of menopause rather than specific to familial or genetic ovarian cancer. Decisions are made by consensus rather than based on individual member's opinion.
Professor Melanie Davies	Committee member	Direct non-financial professional and personal interest	Professional organisation: British Fertility Society. Chair of Special Interest Group for Fertility Preservation, Co-opted member of Executive Committee	2016	13/02/2022	Ongoing	Non-specific. Declare and participate. Rationale: This is a role related to the general topic of fertility rather than specific to familial or genetic ovarian cancer. Decisions are made by consensus rather than based on individual member's opinion.
Professor Melanie Davies	Committee member	Direct non-financial professional and personal interest	Research trial: Chief investigator, POISE study (comparing types of oestrogen replacement for young women). NIHR funded.	2020	13/02/2022	Ongoing – Recruitment commenced July 2022	Specific. Declare and participate. Rationale: This was not published at the time of guideline development and was therefore not included as evidence.
Professor Melanie Davies	Committee member	Direct non-financial professional	Research trial: Chief investigator, BLUSH study: Oxybutynin or venlafaxine for hot flushes in women who cannot or choose not to use hormone replacement therapy:	2021	13/02/2022	Ongoing – trial commencing 1 <sup>st</sup> Sept 2022	Specific. Declare and participate.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
		and personal interest	randomized trial and economic evaluation (comparing types of non-hormonal treatment for hot flushes). NIHR funded.				Rationale: This was not published at the time of guideline development and was therefore not included as evidence.
Professor Melanie Davies	Committee member	Direct non-financial professional and personal interest	Publication. Co-author of recent RCOG Scientific Impact Paper "Risk-reducing salpingo-oophorectomy and the use of hormone replacement therapy below the age of natural menopause".	2021	13/02/2022	Ongoing	Specific. Declare and participate. Rationale: This impact paper was based on consensus and does not necessarily represent the authors individual views.
Professor Melanie Davies	Committee member	Direct non-financial professional and personal interest	Lecturing. Invited speaker on topics of premature ovarian insufficiency and hormone replacement therapy.	2021	13/02/2022	Ongoing	Non-specific. Declare and participate. Rationale: Premature ovarian insufficiency is outside the scope of this guideline.
Professor Gareth Evans	Committee member	Direct financial interest	Salaried job at University of Manchester with paid NHS sessions as Clinical Cancer Geneticist and Professor of Medical Genetics and Cancer epidemiology	October 2013	18/10/2022	Ongoing	Non-specific. Member's paid employment. Declare and participate. Rationale: Salaried employment in higher education (University of Manchester) and in the NHS.
Professor Gareth Evans	Committee member	Direct financial interest	AstraZeneca: Advisory role on PARPi and genetic testing	2015	22/11/2021	2020	Non-specific. Declare and participate. Rationale: This interest is non-specific to the scope of the guideline because the topic of PARP inhibitors is not included.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor Gareth Evans	Committee member	Direct financial interest	AstraZeneca: Advisory role on MEKi in neurofibromatosis	2019	22/11/2021	Ongoing	Non-specific. Declare and participate. Rationale: This interest is non-specific to the scope of the guideline.
Professor Gareth Evans	Committee member	Direct financial interest	Springworks: Advisory role on MEKi in neurofibromatosis	2019	22/11/2021	Ongoing	Non-specific. Declare and participate. Rationale: This interest is non-specific to the scope of the guideline.
Professor Gareth Evans	Committee member	Direct financial interest	Recursion: Advisory role on HDACi in neurofibromatosis	2019	22/11/2021	Ongoing	Non-specific. Declare and participate. Rationale: This interest is non-specific to the scope of the guideline.
Professor Gareth Evans	Committee member	Direct financial interest	AstraZeneca -Consultancy work on genetic testing for BRCA1/2 for PARPi eligibility	2010	07/02/2022	2019	Non-specific. Declare and participate. Rationale: This interest is non-specific to the scope of the guideline because the topic of PARP inhibitors is not included.
Professor Gareth Evans	Committee member	Direct non-financial professional and personal interest	Bowel Cancer UK SAB	2019	22/11/2021	Ongoing	Declare and participate. Rationale: This interest is non-specific to the scope of the guideline.
Professor Gareth Evans	Committee member	Direct non-financial professional	Trial Management Committee ALDO	2019	22/11/2021	Ongoing	Specific. Declare and participate.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
		and personal interest					Rationale: Decisions by this committee are made by consensus with consideration of trial data. The trial and its findings are considered as a separate declaration with decisions to be reviewed during development.
Professor Gareth Evans	Committee member	Direct non-financial professional and personal interest	ALDO study management committee	2018	07/02/2022	2022	Specific. Declare and participate. Rationale: Decisions by this committee are made by consensus with consideration of trial data. The trial and its findings are considered as a separate declaration with decisions to be reviewed during development.
Professor Gareth Evans	Committee member	Direct non-financial professional and personal interest	PROTECT study management committee	2018	07/02/2022	2022	Specific. Declare and participate. Rationale: Decisions by this committee are made by consensus with consideration of trial data. The trial and its findings are considered as a separate declaration with decisions to be reviewed during development.
Professor Gareth Evans	Committee member	Direct financial	Non Executive Director EverythingGenetic Ltd	May 2022	14/06/2022	Ongoing	Specific. Complete exclusion in relation to topics 4 and 5 of the scope Rationale: EverythingGenetic is a commercial company selling genetic tests. Non-executive board members are appointed to maximise shares and

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
							contribute to business progression. Therefore, being involved in this could be perceived as having an impact on what may be recommended for the topic.
Professor Gareth Evans	Committee member	Indirect financial interests	Various grants regarding familial ovarian cancer	Various	22/11/2021	Various	Specific. Declare and participate. Rationale: There is no direct personal financial gain from the grants received.
Professor Gareth Evans	Committee member	Direct non-financial professional and personal interest	D G R Evans, D M Eccles, N Rahman, K Young, M Bulman, E Amir, A Shenton, A Howell, F Laloo. A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet. 2004 Jun;41(6):474-80. doi: 10.1136/jmg.2003.017996.	2004	27/01/2023	Ongoing	Specific. Declare and participate, but not lead topic groups or be involved in the initiation of recommendations This publication was included in evidence report D. Rationale: Whilst this was one of the included studies it was only part of a wider evidence review.
Professor Gareth Evans	Committee member	Direct non-financial professional and personal interest	D G R Evans, F Laloo, A Cramer, E A Jones, F Knox, E Amir, A Howell. Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. J Med Genet 2009 Dec;46(12):811-7. doi: 10.1136/jmg.2009.067850. Epub 2009 Jun 18.	2009	27/01/2023	Ongoing	Specific. Declare and participate, but not lead topic groups or be involved in the initiation of recommendations This publication was included in evidence report D. Rationale: Whilst this was one of the included studies it was only part of a wider evidence base.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor Gareth Evans	Committee member	Direct non-financial professional and personal interest	D Gareth Evans, Elaine F Harkness, Inga Plaskocinska, Andrew J Wallace, Tara Clancy, Emma R Woodward, Tony A Howell, Marc Tischkowitz, Fiona Laloo. Pathology update to the Manchester Scoring System based on testing in over 4000 families. J Med Genet 2017 Oct;54(10):674-681. doi: 10.1136/jmedgenet-2017-104584. Epub 2017 May 10.	2017	27/01/2023	Ongoing	Specific.  Declare and participate, but not lead topic groups or be involved in the initiation of recommendations  This publication was included in evidence report D.  Rationale: Whilst this was one of the included studies it was only part of a wider evidence base.
Professor Gareth Evans	Committee member	Direct non-financial professional and personal interest	Manchanda, Ranjit; Patel, Shreeya; Antoniou, Antonis C; Levy-Lahad, Ephrat; Turnbull, Clare; Evans, D Gareth; Hopper, John L; Macinnis, Robert J; Menon, Usha; Jacobs, Ian; Legood, Rosa. Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry. American journal of obstetrics and gynecology; 2017; vol. 217 (no. 5); 578e1-578e12	2017	27/01/2023	Ongoing	Specific.  Complete exclusion in relation to topics 4 and 5 of the scope (due to another declaration)  This publication was included in evidence report H.  Rationale: This publication contributed substantially to the evidence base.
Professor Gareth Evans	Committee member	Direct non-financial professional and personal interest	D G Evans, K N Gaarenstroom, D Stirling, A Shenton, L Maehle, A Dørum, M Steel, F Laloo, J Apold, M E Porteous, H F A Vasen, C J van Asperen, P Moller. Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet 2009 Sep;46(9):593-7. doi: 10.1136/jmg.2008.058248.	2009	27/01/2023	Ongoing	Specific.  Declare and participate, but not lead topic groups or be involved in the initiation of recommendations  Rationale: This publication was included in evidence report K. An expert witness was invited because there was considerable uncertainty about the details of this publication. The decisions were made in relation to the expert

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
							testimony rather than the publication itself.
Professor Gareth Evans	Committee member	Direct non-financial professional and personal interest	Patel, S., Legood, R., Evans, D.G., Turnbull, C., Antoniou, A.C., Menon, U., Jacobs, I., Manchanda, R., Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women, American journal of obstetrics and gynecology, 218, 431-e1, 2018	2018	27/01/2023	Ongoing	Specific. Complete exclusion in relation to topics 4 and 5 of the scope (due to another declaration) This publication was included in evidence report H. Rationale: This publication contributed substantially to the evidence base.
Professor Gareth Evans	Committee member	Direct non-financial professional and personal interest	L. Sun., M. Sobocan., I. V. Rodriguez., X. Wei., A. Kalra., Oxley., M. Sideris., R.D. Morgan., D. Chandrasekaran., K. Rust., P. Spiliopoulou., R. E. Miller., S. M. Crusz., M. Lockley., N. Singh., A. Faruqi., L. Casey., E. Brockbank., S. Phadnis., T. Mills-Baldock., F. El-Khouly., L. A. Jenkins., A. Wallace., M. Ahmed., A. Kumar., E. M. Swisher., C.Gourley., B. M. Norquist., D. G. Evans., R. Legood., R. Manchanda ., Cost-effectiveness of unselected multigene germline and somatic genetic testing for epithelial ovarian cancer, in publication	2023	27/01/2023	Ongoing	Specific. Complete exclusion in relation to topics 4 and 5 of the scope (due to another declaration) This publication was included in evidence report I. Rationale: This publication was one of a number of studies included as evidence but the member was already excluded due to another declaration.
Professor Gareth Evans	Committee member	Direct non-financial professional and personal interest	Philpott, S., Raikou, M., Manchanda, R., Lockley, M., Singh, N., Scott, M., Evans, D.G., Adlard, J., Ahmed, M., Edmondson, R. and Woodward, E.R., The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in	2022	27/01/2023	Ongoing	Specific. Declare and participate, but not lead topic groups or be involved in the initiation of recommendations Rationale: This publication was included in evidence report K. An expert witness was invited because there was



Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
			BRCA1 and BRCA2, Journal of Medical Genetics, 2022 Oct 10				considerable uncertainty about the details of the economic part of the publication. The decisions were made in relation to the expert testimony rather than the publication itself.
Professor Gareth Evans	Committee member	Direct non-financial professional and personal interest	Crosbie, E.J.; Flaum, N.; Harkness, E.F.; Clayton, R.D.; Holland, C.; Martin-Hirsch, P.; Wood, N.; Keating, P.; Woodward, E.R.; Laloo, F.; Donnai, P.; Edmondson, R.J.; Evans, D.G. Specialist oncological surgery for removal of the ovaries and fallopian tubes in BRCA1 and BRCA2 pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels. International Journal of Cancer; 2021; vol. 148 (no. 5); 1155-1163	2021	24/03/2023	Ongoing	Specific. Declare and participate. Rationale: This publication was included in evidence report N. Whilst there is this study and a number of related studies co-authored by this committee member which are included in the evidence review, they are part of a larger evidence base for this topic and being a co-author on them is unlikely to unduly influence decision making for this topic.
Professor Gareth Evans	Committee member	Direct non-financial professional and personal interest	Domchek, S.M.; Friebel, T.M.; Neuhausen, S.L.; Wagner, T.; Evans, G.; Isaacs, C.; Garber, J.E.; Daly, M.B.; Eeles, R.; Matloff, E.; Tomlinson, G.E.; Van't Veer, L.; Lynch, H.T.; Olopade, O.I.; Weber, B.L.; Rebbeck, T.R. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: A prospective cohort study. Lancet Oncology; 2006; vol. 7 (no. 3); 223-229	2006	24/03/2023	Ongoing	Specific. Declare and participate. Rationale: This publication was included in evidence report N. Whilst there is this study and a number of related studies co-authored by this committee member which are included in the evidence review, they are part of a larger evidence base for this topic and being a co-author on them is unlikely to unduly influence decision making for this topic.
Professor Gareth Evans	Committee member	Direct non-financial professional	Domchek, S.M.; Friebel, T.M.; Singer, C.F.; Gareth Evans, D.; Lynch, H.T.; Isaacs, C.; Garber, J.E.; Neuhausen, S.L.; Matloff, E.;	2010	24/03/2023	Ongoing	Specific. Declare and participate.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
		and personal interest	Eeles, R.; Pichert, G.; Van T'veer, L.; Tung, N.; Weitzel, J.N.; Couch, F.J.; Rubinstein, W.S.; Ganz, P.A.; Daly, M.B.; Olopade, O.I.; Tomlinson, G.; Schildkraut, J.; Blum, J.L.; Rebbeck, T.R. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA; 2010; vol. 304 (no. 9); 967-975				Rationale: This publication was included in evidence report N. Whilst there is this study and a number of related studies co-authored by this committee member which are included in the evidence review, they are part of a larger evidence base for this topic and being a co-author on them is unlikely to unduly influence decision making for this topic.
Professor Gareth Evans	Committee member	Direct non-financial professional and personal interest	Evans, DG; Clayton, R; Donnai, P; Shenton, A; Lalloo, F. Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk. European journal of human genetics; 2009; vol. 17 (no. 11); 1381-1385	2009	24/03/2023	Ongoing	Specific. Declare and participate. Rationale: This publication was included in evidence report N. Whilst there is this study and a number of related studies co-authored by this committee member which are included in the evidence review, they are part of a larger evidence base for this topic and being a co-author on them is unlikely to unduly influence decision making for this topic.
Professor Gareth Evans	Committee member	Direct non-financial professional and personal interest	Gaba, F.; Blyuss, O.; Chandrasekaran, D.; Osman, M.; Goyal, S.; Gan, C.; Izatt, L.; Tripathi, V.; Esteban, I.; McNicol, L.; Ragupathy, K.; Crawford, R.; Evans, D.G.; Legood, R.; Menon, U.; Manchanda, R. Attitudes towards risk-reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study. BJOG: An International Journal of Obstetrics and Gynaecology; 2021; vol. 128 (no. 4); 714-726	2021	24/03/2023	Ongoing	Specific. Declare and participate. Rationale: This publication was included in evidence report N. Whilst there is this study and a number of related studies co-authored by this committee member which are included in the evidence review, they are part of a larger evidence base for this topic and being a co-author on them is unlikely to unduly influence decision making for this topic.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor Gareth Evans	Committee member	Direct non-financial professional and personal interest	Ingham, SL; Sperrin, M; Baildam, A; Ross, GL; Clayton, R; Lalloo, F; Buchan, I; Howell, A; Evans, DG. Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral. Breast cancer research and treatment; 2013; vol. 142 (no. 3); 611-618	2013	24/03/2023	Ongoing	Specific. Declare and participate. Rationale: This publication was included in evidence report N. Whilst there is this study and a number of related studies co-authored by this committee member which are included in the evidence review, they are part of a larger evidence base for this topic and being a co-author on them is unlikely to unduly influence decision making for this topic.
Professor Gareth Evans	Committee member	Direct non-financial professional and personal interest	Kauff, N.D.; Domchek, S.M.; Friebel, T.M.; Robson, M.E.; Lee, J.; Garber, J.E.; Isaacs, C.; Evans, D.G.; Lynch, H.; Eeles, R.A.; Neuhausen, S.L.; Daly, M.B.; Matloff, E.; Blum, J.L.; Sabbatini, P.; Barakat, R.R.; Hudis, C.; Norton, L.; Offit, K.; Rebbeck, T.R. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: A multicenter, prospective study. Journal of Clinical Oncology; 2008; vol. 26 (no. 8); 1331-1337	2008	24/03/2023	Ongoing	Specific. Declare and participate. Rationale: This publication was included in evidence report N. Whilst there is this study and a number of related studies co-authored by this committee member which are included in the evidence review, they are part of a larger evidence base for this topic and being a co-author on them is unlikely to unduly influence decision making for this topic.
Professor Gareth Evans	Committee member	Direct non-financial professional and personal interest	Marcinkute, R.; Woodward, E.R.; Gandhi, A.; Howell, S.; Crosbie, E.J.; Wissely, J.; Harvey, J.; Highton, L.; Murphy, J.; Holland, C.; Edmondson, R.; Clayton, R.; Barr, L.; Harkness, E.F.; Howell, A.; Lalloo, F.; Evans, D.G. Uptake and efficacy of bilateral risk reducing surgery in unaffected female BRCA1 and BRCA2 carriers. Journal of	2022	24/03/2023	Ongoing	Specific. Declare and participate. Rationale: This publication was included in evidence report N. Whilst there is this study and a number of related studies co-authored by this committee member which are included in the evidence review, they are part of a larger

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
			Medical Genetics; 2022; vol. 59 (no. 2); 133-140				evidence base for this topic and being a co-author on them is unlikely to unduly influence decision making for this topic.
Professor Gareth Evans	Committee member	Direct non-financial professional and personal interest	Rebbeck, TR; Lynch, HT; Neuhausen, SL; Narod, SA; Van't Veer, L; Garber, JE; Evans, G; Isaacs, C; Daly, MB; Matloff, E; et, al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. New England journal of medicine; 2002; vol. 346 (no. 21); 1616-1622	2002	24/03/2023	Ongoing	Specific. Declare and participate. Rationale: This publication was included in evidence report N. Whilst there is this study and a number of related studies co-authored by this committee member which are included in the evidence review, they are part of a larger evidence base for this topic and being a co-author on them is unlikely to unduly influence decision making for this topic.
Professor Gareth Evans	Committee member	Direct non-financial professional and personal interest	ESMO guideline group on management of HBOC gene carriers	2021	07/02/2022	September 2022	Non-specific. Declare and participate. Rationale: This is not specific to the scope of the guideline.
Professor Gareth Evans	Committee member	Direct non-financial professional and personal interest	Challberg, J; Ashcroft, L; Laloo, F; Eckersley, B; Clayton, R; Hopwood, P; Selby, P; Howell, A; Evans, D G. Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT. British journal of cancer 105(1): 22-7, 2011	2011	12/05/2023	Ongoing	Specific. Declare and participate. Rationale: This publication was included in evidence report P. Whilst there is this study and a number of related studies co-authored by this committee member which are included in the evidence review, they are part of a larger evidence base for this topic and being a co-author on them is unlikely to unduly influence decision making for this topic.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor Gareth Evans	Committee member	Direct non-financial professional and personal interest	Gaba, F; Blyuss, O; Chandrasekaran, D; Osman, M; Goyal, S; Gan, C; Izatt, L; Tripathi, V; Esteban, I; McNicol, L; Ragupathy, K; Crawford, R; Evans, D G; Legood, R; Menon, U; Manchanda, R. Attitudes towards risk-reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study. BJOG: an international journal of obstetrics and gynaecology 128(4): 714-726, 2021	2021	12/05/2023	Ongoing	Specific. Declare and participate. Rationale: This publication was included in evidence report P. Whilst there is this study and a number of related studies co-authored by this committee member which are included in the evidence review, they are part of a larger evidence base for this topic and being a co-author on them is unlikely to unduly influence decision making for this topic.
Professor Gareth Evans	Committee member	Direct non-financial professional and personal interest	Guideline publication with ESMO. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.  Sessa C, Balmaña J, Bober SL, Cardoso MJ, Colombo N, Curigliano G, Domchek SM, Evans DG, Fischerova D, Harbeck N, Kuhl C, Lemley B, Levy-Lahad E, Lambertini M, Ledermann JA, Loibl S, Phillips KA, Paluch-Shimon S; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org.  Ann Oncol. 2023 Jan;34(1):33-47. Doi: 10.1016/j.annonc.2022.10.004.	January 2023	08.06.2023	January 2023	Specific. Declare and participate. Rationale: Whilst this includes ovarian cancer it is broader than the scope with a focus on both breast and ovarian cancer. Decisions related to this guidance were based on consensus rather than reflect the committee members individual opinion.
Professor Gareth Evans	Committee member	Indirect financial interest	Population BRCA testing Grant Yorkshire Cancer (PI Ranjit Manchanda)	2022	13/04/2022	Ongoing	Specific. Declare and participate. Rationale: Even though directly related to the scope of the guideline, this is an

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
							indirect interest without any personal financial gain.
Dr Judith Hayward	Committee member	Direct financial interest	Salaried GP: Shipley Medical Practice, Affinity Care	January 2014	01/11/2022	Ongoing	Non-specific. Member's paid employment. Declare and participate. Rationale: Salaried employment in the NHS.
Dr Judith Hayward	Committee member	Direct financial interest	GPwSI in Genetics: Yorkshire Regional Genetics Service. Employed by and seconded from Shipley Medical Practice, Affinity Care.	January 2014	01/11/2022	Ongoing	Non-specific. Declare and participate. Rationale: This is part of the member's salaried employment in the NHS.
Dr Judith Hayward	Committee member	Direct financial interest	Paid roles (not employed): Primary Care Lead, NEY GMSA	April 2021	01/11/2022	Ongoing	Non-specific. Declare and participate. Rationale: This is in addition to the member's salaried employment in the NHS – a role as the primary care lead for the for the North East Yorkshire Genomic Medicine Service Alliance which is part of the NHS.
Dr Judith Hayward	Committee member	Direct financial interest	Contracted role to Affinity Care: Primary Care Adviser, Health Education England	June 2022	01/11/2022	June 2024	Non-specific. Declare and participate. Rationale: This is a salaried role in an executive non-departmental public body of the Department of Health and Social Care.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Judith Hayward	Committee member	Direct financial interest	GP Adviser (Consultancy work) to Congenica LTD. This pertains specifically to a research project within the NIHR portfolio (HAPPY Project) which is solely concerned with Pharmacogenomics within Primary Care. There is no overlap with Familial Ovarian Cancer.	Pre-January 2021	17/02/2022	Ongoing	Non-specific. Declare and participate. Rationale: This interest is non-specific to the scope of the guideline.
Dr Judith Hayward	Committee member	Direct financial interest	Honorarium received (£250) from Pulse (Cogora) to deliver educational presentation entitled "Genomics for GPs: Current practice and future potential" which included slides regarding management of patients with a family history of ovarian cancer	March 2023	02/06/2023	March 2023	Specific. Declare and participate. Rationale: Cogora is a healthcare marketing agency that runs webinars for GPs. Whilst this interest is related to the scope, the presentation was educational and more focused on current practice. It did not include details of potential recommendations or discussions.
Dr Judith Hayward	Committee member	Direct non-financial professional and personal interest	RCGP Joint Clinical Champion for Genomics in Primary Care	Pre-January 2021	17.02.2022	Ongoing	Non-specific. Declare and participate. Rationale: This is a non-financial non-specific role.
Dr Judith Hayward	Committee member	Direct non-financial professional and personal interest	Primary Care Adviser to HEE Genomics Education Programme	Pre-January 2021	17.02.2022	Ongoing	Non-specific. Declare and participate. Rationale: This is a non-financial non-specific advisory role.
Dr Judith Hayward	Committee member	Direct non-financial professional	Member of the NHSE CRG for Genomic Medicine	Pre-January 2021	17.02.2022	Ongoing	Specific. Declare and participate.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
		and personal interest					Rationale: This is a membership rather than a chairing role for this clinical reference group.
Dr Judith Hayward	Committee member	Direct non-financial professional and personal interest	Co-chair Primary Care SIG (within NHSE/I / HEE GEP Workforce Steering Group)	Pre-January 2021	17.02.2022	Ongoing	Specific. Declare and participate. Rationale: Decisions by this group are made by consensus.
Dr Judith Hayward	Committee member	Direct non-financial professional and personal interest	Member of the Genomics England Primary Care Network and Steering Group	Pre-January 2021	17.02.2022	Ongoing	Specific. Declare and participate. Rationale: Decisions by this group are made by consensus.
Dr Judith Hayward	Committee member	Direct non-financial professional and personal interest	Principal Investigator for PRINCIPLE trial on behalf of Shipley Medical Practice	Pre-January 2021	17.02.2022	May 2023	Non-specific. Declare and participate. Rationale: This interest is non-specific to the scope of the guideline.
Dr Judith Hayward	Committee member	Direct non-financial professional and personal interest	Member of Genomics Professionals Partnership Group, AoMRC (representing RCGP)	Pre-January 2021	17.02.2022	Ongoing	Non-specific. Declare and participate. Rationale: Decisions by this group are made by consensus.
Dr Judith Hayward	Committee member	Direct non-financial professional and personal interest	Member of Primary Care Liaison Group, Our Future Health	Pre-January 2021	17.02.2022	Ongoing	Non-specific. Declare and participate. Rationale: Decisions by this group are made by consensus.



Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Judith Hayward	Committee member	Direct non-financial professional and personal interest	Population BRCA testing Grant Yorkshire Cancer (PI Ranjit Manchanda)	2022	14.06.2022	Ongoing	Declare and participate. Rationale: The committee member is not the principal investigator and there is no financial gain associated with this.
Dr Judith Hayward	Committee member	Direct non-financial professional and personal interest	Co-author of Joint RCGP and BSGM guidance: Direct-to-consumer testing	2022	14.10.2022	Ongoing	Specific. Declare and participate. Rationale: This interest is specific to the guideline but the guidance is based on consensus and not necessarily the authors own opinion.
Dr Judith Hayward	Committee member	Direct non-financial professional and personal interest	Received travel expenses from Best Practice to deliver educational presentations within Best Practice London 2023. No expenses requested or received to deliver education presentation within Oncology Professional Practice 2023	March 2023	02.06.2023	May 2023	Non-specific. Non-specific. Declare and participate. Rationale: This interest is not specific to the scope of the guideline.
Dr Judith Hayward	Committee member	Indirect non-financial professional and personal interest	My husband is a Clinical Partner and Medical Director of a Primary Care Network (which is also a GP partnership): Affinity Care	Pre-January 2021	17.02.2022	Ongoing	Non-specific. Declare and participate. Rationale: This interest is non-specific to the scope of the guideline.
Professor Ranjit Manchanda	Topic Adviser	Direct financial interest	Paid Employment – Queen Mary University of London (primary employer). Full time employment as Professor of Gynaecological Oncology. Academic component = 7PA (0.7FTE)	June 2015	24.10.2022	Ongoing	Non-specific. Member's paid employment.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
							Declare and participate. Rationale: Salaried employment in higher education (Queen Mary University of London).
Professor Ranjit Manchanda	Topic Adviser	Direct financial interest	Employment – Barts Health NHS Trust. Professor of Gynaecological Oncology. Clinical component 3 PA (0.3 FTE). This is paid to QMUL as a recharge.	June 2015	24.10.2022	Ongoing	Non-specific. Member's paid employment. Declare and participate. Rationale: Salaried employment in the NHS.
Professor Ranjit Manchanda	Topic Adviser	Direct financial interest	Employment – Health Education England. Integrated Academic Training Programme Director, London School of Obstetrics & Gynaecology. 1PA (0.1FTE). This is paid to QMUL as a recharge.	May 2019	24.10.2022	Ongoing	Non-specific. Member's paid employment. Declare and participate. Rationale: Part of the salaried employment in higher education (Queen Mary University of London).
Professor Ranjit Manchanda	Topic Adviser	Direct financial interest	Employment – NIHR (National Institute of Health Research). Speciality Research Lead for Gynaecological Cancer North Thames Clinical Research Network. 0.25PA (0.025FTE). This is paid to QMUL as a recharge.	April 2020	24.10.2022	Ongoing	Non-specific. Member's paid employment. Declare and participate. Rationale: Part of salaried employment in higher education (Queen Mary University of London).
Professor Ranjit Manchanda	Topic Adviser	Direct financial interest	Lecture fees- talk on ovarian cancer at RCGP symposium– Annual meeting Royal College of General Practitioners from AstraZeneca	15.10.2021	13.09.2021	15.10.2021	Specific. Declare and participate, but not lead topic groups or be involved in the initiation of recommendations.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
			Unravelling symptom complexities and effective referral using the 3S approach. (covers current need – burden of disease, lack of screening, acting on symptoms to improve time to diagnosis for ovarian cancer). One of 3 speakers.				Rationale: Due to the number of declared interests and overlap with the guideline the decision was taken that the topic adviser should not lead topic groups or be involved in initiating of recommendations in this area.
Professor Ranjit Manchanda	Topic Adviser	Direct financial interest	Advisory body meeting GSK – meeting attendance	28.09.2021	13.09.2021	28.09.2021	Specific.  Declare and participate, but not lead topic groups or be involved in the initiation of recommendations.  Rationale: Due to the number of declared interests and overlap with the guideline the decision was taken that the topic adviser should not lead topic groups or be involved in initiating of recommendations in this area.
Professor Ranjit Manchanda	Topic Adviser	Direct financial interest	Lecture fees on genetic testing from Astrazeneca:  Role of the Gynaecologist in BRCA testing. Webinar, FOGSI (Federation of Obstetrics & Gynaecologists of India), 30th July 2020	30.07.2020	13.09.2021	30.07.2020	Specific.  Declare and participate, but not lead topic groups or be involved in the initiation of recommendations.  Rationale: Due to the number of declared interests and overlap with the guideline the decision was taken that the topic adviser should not lead topic groups or be involved in initiating of recommendations in this area.
Professor Ranjit Manchanda	Topic Adviser	Direct financial interest	Lecture fees on Biomarkers in Gynaecological Cancer from GSK:	14.06.2021	13.09.2021	14.06.2021	Specific.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
			The impact of digital health on biomarker testing. GSK Biomarkers in Oncology Educational meeting. 14 <sup>th</sup> June 2021				Declare and participate, but not lead topic groups or be involved in the initiation of recommendations.  Rationale: Due to the number of declared interests and overlap with the guideline the decision was taken that the topic adviser should not lead topic groups or be involved in initiating of recommendations in this area.
Professor Ranjit Manchanda	Topic Adviser	Direct financial interest	Lecture fees on genetic testing from AstraZeneca:  Emerging role of the gynecologist in testing for BRCA mutations in ovarian cancer. International Webinar	17.10.2019	13.09.2021	17.10.2019	Specific.  Declare and participate, but not lead topic groups or be involved in the initiation of recommendations  Rationale: Due to the number of declared interests and overlap with the guideline the decision was taken that the topic adviser should not lead topic groups or be involved in initiating of recommendations in this area.
Professor Ranjit Manchanda	Topic Adviser	Direct financial interest	Private practice in gynaecological oncology (small/nascent) and is no different to NHS practice. Outside of NHS working hours.	February 2020	13.09.2021	Ongoing	Specific.  Declare and participate, but not lead topic groups or be involved in the initiation of recommendations.  Rationale: Due to the number of declared interests and overlap with the guideline the decision was taken that the topic adviser should not lead topic groups or be involved in initiating of recommendations in this area.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor Ranjit Manchanda	Topic Adviser	Direct financial interest	<p>Non-executive Director for EverythingGenetic Limited.</p> <p>The company EGL is involved in genetic testing which is both non cancer related and cancer related. It currently offers testing for COVID and multiple cancers such as breast, colorectal, prostate, urological, ovarian, haematological, etc. including testing related to cancer treatment/therapy</p> <p>I would be spending around 2-3 hours of my time, 3-4 times a year attending a board meeting. I get a small honorarium for attending a board meeting. I do not get a salary or get/hold any stocks or shares. I do not believe that my role is relevant to the scope of the guideline. The functioning of the company is completely independent of the guideline</p>	June 2022	19/06/2022	Ongoing	<p>Specific.</p> <p>Complete exclusion in relation to topics 4 and 5 of the scope.</p> <p>Rationale: EverythingGenetic is a commercial company selling genetic tests. Non-executive board members are appointed to maximise shares and contribute to business progression. Therefore, being involved in this could be perceived as having an impact on what may be recommended for the topic.</p>
Professor Ranjit Manchanda	Topic Adviser	Direct non-financial professional and personal interest	Extensive PPI activity working with multiple charities and patient support groups on issues related to management of familial ovarian cancer	Various dates	13.09.2021	Ongoing	<p>Specific.</p> <p>Declare and participate, but not lead topic groups or be involved in the initiation of recommendations.</p> <p>Rationale: Due to the number of declared interests and overlap with the guideline the decision was taken that the topic adviser should not lead topic groups or be involved in initiating of recommendations in this area.</p>

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor Ranjit Manchanda	Topic Adviser	Direct non-financial professional and personal interest	Scientific Adviser to patient support group BRCA Umbrella	2014	13.09.2021	Ongoing	<p>Specific.</p> <p>Declare and participate, but not lead topic groups or be involved in the initiation of recommendations.</p> <p>Rationale: Due to the number of declared interests and overlap with the guideline the decision was taken that the topic adviser should not lead topic groups or be involved in initiating of recommendations in this area.</p>
Professor Ranjit Manchanda	Topic Adviser	Direct non-financial professional and personal interest	Scientific Adviser to patient support group GO Girls	2020	13.09.2021	Ongoing	<p>Specific.</p> <p>Declare and participate, but not lead topic groups or be involved in the initiation of recommendations</p> <p>Rationale: Due to the number of declared interests and overlap with the guideline the decision was taken that the topic adviser should not lead topic groups or be involved in initiating of recommendations in this area.</p>
Professor Ranjit Manchanda	Topic Adviser	Direct non-financial professional and personal interest	Member Trial Steering Committee and Trial Management group, UKFOCSS (United Kingdom Familial Ovarian Cancer Screening Study)	2008	13.09.2021	2017	<p>Specific.</p> <p>Declare and participate, but not lead topic groups or be involved in the initiation of recommendations.</p> <p>Rationale: Due to the number of declared interests and overlap with the guideline the decision was taken that the topic adviser should not lead topic</p>

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
							groups or be involved in initiating of recommendations in this area.
Professor Ranjit Manchanda	Topic Adviser	Direct non-financial professional and personal interest	Member Trial Steering Committee and Trial Management group, ALDO (Avoiding Late Diagnosis in Ovarian Cancer) study	2018	13.09.2021	Ongoing	Specific. Declare and participate, but not lead topic groups or be involved in the initiation of recommendations  Rationale: Due to the number of declared interests and overlap with the guideline the decision was taken that the topic adviser should not lead topic groups or be involved in initiating of recommendations in this area.
Professor Ranjit Manchanda	Topic Adviser	Direct non-financial professional and personal interest	Chief Investigator PROTECTOR (Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal) study.  UK study investigating early salpingectomy for prevention of ovarian cancer  (research grant from Barts Charity and Rosetrees Trust)	2018	13.09.2021	Ongoing	Specific. Declare and participate, but not lead topic groups or be involved in the initiation of recommendations.  Rationale: Due to the number of declared interests and overlap with the guideline the decision was taken that the topic adviser should not lead topic groups or be involved in initiating of recommendations in this area.
Professor Ranjit Manchanda	Topic Adviser	Direct non-financial professional and personal interest	Chief Investigator SIGNPOST (Systematic genetic testing for personalised ovarian cancer therapy) study  UK study on genetic testing in ovarian cancer  (research grant from Barts Charity)	2016	13.09.2021	Ongoing	Specific. Declare and participate, but not lead topic groups or be involved in the initiation of recommendations  Rationale: Due to the number of declared interests and overlap with the guideline the decision was taken that the

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
							topic adviser should not lead topic groups or be involved in initiating of recommendations in this area.
Professor Ranjit Manchanda	Topic Adviser	Direct non-financial professional and personal interest	PI for PROMISE feasibility Study – Pilot study on providing personalized ovarian cancer risk prediction for UK women through population testing.  (research grant from Eve Appeal and CRUK)	2016	13.09.2021	2020	Specific.  Declare and participate, but not lead topic groups or be involved in the initiation of recommendations.  Rationale: Due to the number of declared interests and overlap with the guideline the decision was taken that the topic adviser should not lead topic groups or be involved in initiating of recommendations in this area.  This study was not published during guideline development and therefore was not part of the included evidence.
Professor Ranjit Manchanda	Topic Adviser	Direct non-financial professional and personal interest	Chief Investigator DETECT Study (Direct to Patient testing at Cancer diagnosis for Precision Prevention-2.)  Randomised trial comparing direct to patient genetic testing with mainstreaming genetic testing at cancer diagnosis - for endometrial cancer, colorectal cancer and ovarian cancer.  (research grant from North East London Cancer Alliance and from GSK)	2021	13.09.2021	2025	Specific.  Declare and participate, but not lead topic groups or be involved in the initiation of recommendations.  Rationale: Due to the number of declared interests and overlap with the guideline the decision was taken that the topic adviser should not lead topic groups or be involved in initiating of recommendations in this area.  This study was not published during guideline development and therefore was not part of the included evidence.



Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor Ranjit Manchanda	Topic Adviser	Direct non-financial professional and personal interest	<p>UKCOGS (United Kingdom COVID and Gynaecological Cancer Study).</p> <p>National audit of changes to MDT practice and gynaecological cancer outcomes during the COVID pandemic</p> <p>research grant research grant funding from BGCS (British Gynaecological Cancer Society)</p>	2020	13.09.2021	2023	<p>Non-specific.</p> <p>Declare and participate, but not lead topic groups or be involved in the initiation of recommendations.</p> <p>Rationale: Due to the number of declared interests and overlap with the guideline the decision was taken that the topic adviser should not lead topic groups or be involved in initiating of recommendations in this area.</p> <p>This is non-specific to the scope of the guideline.</p>
Professor Ranjit Manchanda	Topic Adviser	Direct non-financial professional and personal interest	<p>Member British Gynaecological Cancer Society and British Association of Gynaecological Pathology Guideline committee on Genetic testing in Ovarian Cancer.</p> <p>Sundar S, Manchanda R, Gourley C, George A, Wallace A, Balega J, Williams S, Wallis Y, Edmondson R, Nicum S, Frost J, Attygalle A, Fotopoulou C, Bowen R, Bell D, Gajjar K, Ramsay B, Wood N, Ghaem-Maghani S, Miles T, Ganesan R. British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for germline and tumour testing for BRCA1/2 variants in ovarian cancer in the United Kingdom. Int J Gynecol Cancer 2021;0:1–7. doi:10.1136/ijgc-2020-002112</p>	2020	13.09.2021	2021	<p>Specific.</p> <p>Declare and participate, but not lead topic groups or be involved in the initiation of recommendations.</p> <p>Rationale: This publication was not included because it did not match the criteria (was a consensus paper rather than research study).</p>

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor Ranjit Manchanda	Topic Adviser	Indirect financial interest	<p>Chief investigator and received research funding for the research studies listed in section above. All my grants are held and handled by QMUL. No funds are directly given to me. I hold no stocks or shares or IP.</p> <p>SIGNPOST (research grant funding from Barts Charity)</p> <p>PROTECTOR (research grant funding from Barts Charity and Rosetrees Trust)</p> <p>UKCOGS (United Kingdom COVID and Gynaecological Cancer Study) - research grant research grant funding from BGCS (British Gynaecological Cancer Society)</p> <p>Population testing research (research grant funding from Eve Appeal)</p> <p>DETECT (research grant Funding from North East London Cancer Alliance and from GSK)</p> <p>NHS Innovation Accelerator Fellowship for population BRCA testing (Grant from NIA)</p>	Commenced Pre-January 2022	13.09.2021	Ongoing	<p>Specific.</p> <p>Declare and participate, but not lead topic groups or be involved in the initiation of recommendations</p> <p>Rationale: Due to the number of declared interests and overlap with the guideline the decision was taken that the topic adviser should not lead topic groups or be involved in initiating of recommendations in this area.</p>
Professor Ranjit Manchanda	Topic Adviser	Indirect financial interest	<p>PROTECT- Population based Germline testing for Early detection and Cancer Prevention. Grant funding to Queen Mary University of London.</p> <p>Grant from Yorkshire Cancer Research Charity.</p> <p>Role - Chief Investigator</p>	2022	13/04/2022	Ongoing	<p>Specific.</p> <p>Declare and participate.</p> <p>Rationale: Even though directly related to the scope of the guideline, this is an indirect interest without any personal financial gain.</p>

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor Ranjit Manchanda	Topic Adviser	Indirect financial interest	<p>DETECT-2 - Direct to Patient testing at Cancer diagnosis for Precision Prevention-2. Grant funding to Queen Mary University of London.</p> <p>Grant from GSK. This is an investigator led patient awareness study. (This is not a Drug or CTIMP trial)</p> <p>Role - Chief Investigator</p>	2022	13/04/2022	Ongoing	<p>Specific.</p> <p>Declare and participate.</p> <p>Rationale: Even though directly related to the scope of the guideline, this is an indirect interest without any personal financial gain.</p>
Professor Ranjit Manchanda	Topic Adviser	Indirect financial interest	<p>Ovacure Innovation Challenge research grant funding award. This provides seed funding for research into development/validation of new biomarkers for ovarian cancer screening in asymptomatic women and diagnostic testing for detecting ovarian cancer in symptomatic women. Role: Project Co-Lead</p>	21/09/2022	24/10/2022	Ongoing	<p>Specific.</p> <p>Declare and participate, but not lead topic groups or be involved in the initiation of recommendations.</p> <p>Rationale: Due to the number of declared interests and overlap with the guideline the decision was taken that the topic adviser should not lead topic groups or be involved in initiating of recommendations in this area.</p>
Professor Ranjit Manchanda	Topic Adviser	Direct non-financial professional and personal interest	<p>Chair and organisation of 'State of the art: Prevention strategies in high risk women'. ESGO conference, Prague 2021</p>	August 2021	August 2021	2021	<p>Specific.</p> <p>Declare and participate, but not lead topic groups or be involved in the initiation of recommendations.</p> <p>Rationale: Due to the number of declared interests and overlap with the guideline the decision was taken that the topic adviser should not lead topic groups or be involved in initiating of recommendations in this area.</p>

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor Ranjit Manchanda	Topic Adviser	Direct non-financial professional and personal interest	Prevention in hereditary and non-hereditary ovarian cancer. Swedish Cancer Society meeting Future perspectives in Ovarian Cancer research, Stockholm 24-25 Nov 2022	November 2022	August 2021	2022	Specific. Declare and participate, but not lead topic groups or be involved in the initiation of recommendations  Rationale: Due to the number of declared interests and overlap with the guideline the decision was taken that the topic adviser should not lead topic groups or be involved in initiating of recommendations in this area.
Professor Ranjit Manchanda	Topic Adviser	Direct non-financial professional and personal interest	Diagnostic testing & biomarkers- the right to test! ENGAGE Patient Advocacy Seminar 2021, within the ESGO Congress in October 2021, Prague.	October 2021	August 2021	2021	Specific. Declare and participate, but not lead topic groups or be involved in the initiation of recommendations.  Rationale: Due to the number of declared interests and overlap with the guideline the decision was taken that the topic adviser should not lead topic groups or be involved in initiating of recommendations in this area.
Professor Ranjit Manchanda	Topic Adviser	Direct non-financial professional and personal interest	Manchanda R, Burnell M, Loggenberg K, Desai R, Wardle J, Sanderson SC, Gessler S, Side L, Balogun N, Kumar A, Dorkins H., Cluster-randomised non-inferiority trial comparing DVD-assisted and traditional genetic counselling in systematic population testing for BRCA1/2 mutations. Journal of medical genetics, 53, 472-80, 2016	2016	06/06/2022	Ongoing	Specific. Declare and participate, but not lead topic groups or be involved in the initiation of recommendations  Rationale: This publication was included in evidence report <b>B</b> . This is only one part of a considerable evidence base for this topic and being the first author is

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
							unlikely to unduly influence decision making for this topic.
Professor Ranjit Manchanda	Topic Adviser	Direct non-financial professional and personal interest	Manchanda, Ranjit; Patel, Shreeya; Antoniou, Antonis C; Levy-Lahad, Ephrat; Turnbull, Clare; Evans, D Gareth; Hopper, John L; Macinnis, Robert J; Menon, Usha; Jacobs, Ian; Legood, Rosa. Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry. American journal of obstetrics and gynecology; 2017; vol. 217 (no. 5); 578e1-578e12	2017	27/01/2023	Ongoing	Specific. Complete exclusion in relation to topics 4 and 5 of the scope (due to another declaration). This publication was included in evidence report H. Rationale: This publication contributed substantially to the evidence base.
Professor Ranjit Manchanda	Topic Adviser	Direct non-financial professional and personal interest	R Manchanda, M Burnell, F Gaba, R Desai, J Wardle, S Gessler, L Side, S Sanderson, K Loggenberg, AF Brady, H Dorkins, Y Wallis, C Chapman, C Jacobs, R Legood, U Beller, I Tomlinson, U Menon, I Jacobs Randomised trial of population-based BRCA testing in Ashkenazi Jews: long-term outcomes, First published: 10 September 2019 <a href="https://doi.org/10.1111/1471-0528.15905">https://doi.org/10.1111/1471-0528.15905</a>	2019	27/01/2023	Ongoing	Specific. Complete exclusion in relation to topics 4 and 5 of the scope (due to another declaration). This publication was included in evidence report H. Rationale: This publication contributed substantially to the evidence base.
Professor Ranjit Manchanda	Topic Adviser	Direct non-financial professional and personal interest	Manchanda, R., Legood, R., Burnell, M., McGuire, A., Raikou, M., Loggenberg, K., et al., Cost-effectiveness of population screening for BRCA mutations in Ashkenazi Jewish women compared with family history-based testing, JNCI: Journal of the National Cancer Institute, 107, 2015	2015	27/01/2023	Ongoing	Specific. Complete exclusion in relation to topics 4 and 5 of the scope (due to another declaration). This publication was included in evidence report H. Rationale: This publication contributed substantially to the evidence base.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor Ranjit Manchanda	Topic Adviser	Direct non-financial professional and personal interest	Patel, S., Legood, R., Evans, D.G., Turnbull, C., Antoniou, A.C., Menon, U., Jacobs, I., Manchanda, R., Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women, American journal of obstetrics and gynecology, 218, 431-e1, 2018	2018	27/01/2023	Ongoing	Specific. Complete exclusion in relation to topics 4 and 5 of the scope (due to another declaration). This publication was included in evidence report H. Rationale: This publication contributed substantially to the evidence base.
Professor Ranjit Manchanda	Topic Adviser	Direct non-financial professional and personal interest	L. Sun., M. Sobocan., I. V. Rodriguez., X. Wei., A. Kalra., Oxley., M. Sideris., R.D. Morgan., D. Chandrasekaran., K. Rust., P. Spiliopoulou., R. E. Miller., S. M. Crusz., M. Lockley., N. Singh., A. Faruqi., L. Casey., E. Brockbank., S. Phadnis., T. Mills-Baldock., F. El-Khouly., L. A. Jenkins., A. Wallace., M. Ahmed., A. Kumar., E. M. Swisher., C.Gourley., B. M. Norquist., D. G. Evans., R. Legood., R. Manchanda ., Cost-effectiveness of unselected multigene germline and somatic genetic testing for epithelial ovarian cancer, in publication	2023	27/01/2023	Ongoing	Specific. Complete exclusion in relation to topics 4 and 5 of the scope (due to another declaration). This publication was included in evidence report I. Rationale: This was one of a number of publications included in the evidence. However, due to another declaration the member was not taking part in discussions or decision making in relation to this topic.
Professor Ranjit Manchanda	Topic Adviser	Direct non-financial professional and personal interest	Philpott, S., Raikou, M., Manchanda, R., Lockley, M., Singh, N., Scott, M., Evans, D.G., Adlard, J., Ahmed, M., Edmondson, R. and Woodward, E.R., The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2, Journal of Medical Genetics, 2022 Oct 10	2022	27/01/2023	October 2022	Specific. Declare and participate, but not lead topic groups or be involved in the initiation of recommendations. Rationale: This publication was included in evidence report K. An expert witness was invited because there was considerable uncertainty about the details of the economic part of this

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
							publication. The decisions were made in relation to the expert testimony rather than the publication itself.
Professor Ranjit Manchanda	Topic Adviser	Direct non-financial professional and personal interest	Manchanda, R., Legood, R., Pearce, L., & Menon, U. (2015). Defining the risk threshold for risk reducing salpingo-oophorectomy for ovarian cancer prevention in low risk postmenopausal women. <i>Gynecologic oncology</i> , 139(3), 487-494.	2015	27/01/2023	Ongoing	Specific.  Declare and participate, but not lead topic groups or be involved in the initiation of recommendations.  Rationale: This publication was included in evidence report N. This is only one part of a considerable evidence base for this topic and being the author is unlikely to unduly influence decision making for this topic.
Professor Ranjit Manchanda	Topic Adviser	Direct non-financial professional and personal interest	Manchanda, R., Legood, R., Antoniou, A. C., Gordeev, V. S., & Menon, U. (2016). Specifying the ovarian cancer risk threshold of 'premenopausal risk-reducing salpingo-oophorectomy' for ovarian cancer prevention: a cost-effectiveness analysis. <i>Journal of medical genetics</i> , 53(9), 591-599.	2016	27/01/2023	Ongoing	Specific.  Declare and participate, but not lead topic groups or be involved in the initiation of recommendations.  Rationale: This publication was included in evidence report N. This is only one part of a considerable evidence base for this topic and being the author is unlikely to unduly influence decision making for this topic.
Professor Ranjit Manchanda	Topic Adviser	Direct non-financial professional and personal interest	Gaba, F.; Blyuss, O.; Chandrasekaran, D.; Osman, M.; Goyal, S.; Gan, C.; Izatt, L.; Tripathi, V.; Esteban, I.; McNicol, L.; Ragupathy, K.; Crawford, R.; Evans, D.G.; Legood, R.; Menon, U.; Manchanda, R. Attitudes towards risk-reducing early salpingectomy with delayed oophorectomy	2021	24/03/2023	Ongoing	Specific.  Declare and participate.  Rationale: This publication was included in evidence report N. Whilst there is this study and a number of related studies authored or co-authored by this

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
			for ovarian cancer prevention: a cohort study. BJOG: An International Journal of Obstetrics and Gynaecology; 2021; vol. 128 (no. 4); 714-726				committee member which are included in the evidence review, they are part of a larger evidence base for this topic and being a co-author on them is unlikely to unduly influence decision making for this topic.
Professor Ranjit Manchanda	Topic Adviser	Direct non-financial professional and personal interest	Gaba, F.; Manchanda, R. Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers. Best Practice and Research: Clinical Obstetrics and Gynaecology; 2020; vol. 65; 46-65	2020	24/03/2023	Ongoing	Specific. Declare and participate. Rationale: This publication was included in evidence report N. Whilst there is this study and a number of related studies authored or co-authored by this committee member which are included in the evidence review, they are part of a larger evidence base for this topic and being a co-author on them is unlikely to unduly influence decision making for this topic.
Professor Ranjit Manchanda	Topic Adviser	Direct non-financial professional and personal interest	Xia Wei X; Oxley S; Sideris M; Karla A; Brentnall A; Sun L; Yang L; Legood R; Manchanda R. Quality of life after risk-reducing surgery for breast and ovarian cancer prevention: a systematic review and meta-analysis. 2023	2023	24/03/2023	Ongoing	Specific. Declare and participate. Rationale: This publication was included in evidence <b>report N</b> . Whilst there is this study and a number of related studies authored or co-authored by this committee member which are included in the evidence review, they are part of a larger evidence base for this topic and being a co-author on them is unlikely to unduly influence decision making for this topic.



Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor Ranjit Manchanda	Topic Adviser	Direct non-financial professional and personal interest	Manchanda, R., Legood, R., Pearce, L., & Menon, U. (2015). Defining the risk threshold for risk reducing salpingo-oophorectomy for ovarian cancer prevention in low-risk postmenopausal women. <i>Gynecologic oncology</i> , 139, 487-94.	2015	27/03/2023	Ongoing	Specific. Declare and participate.  Rationale: This publication was included in evidence report N. Whilst there is this study and a number of related studies authored or co-authored by this committee member which are included in the evidence review, they are part of a larger evidence base for this topic and being a co-author on them is unlikely to unduly influence decision making for this topic.
Professor Ranjit Manchanda	Topic Adviser	Direct non-financial professional and personal interest	Gaba, F; Blyuss, O; Chandrasekaran, D; Osman, M; Goyal, S; Gan, C; Izatt, L; Tripathi, V; Esteban, I; McNicol, L; Ragupathy, K; Crawford, R; Evans, D G; Legood, R; Menon, U; Manchanda, R. Attitudes towards risk-reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study. <i>BJOG: an international journal of obstetrics and gynaecology</i> 128(4): 714-726, 2021	2021	12/05/2023	Ongoing	Specific. Declare and participate.  Rationale: This publication was included in evidence report P. Whilst there is this study and a number of related studies authored or co-authored by this committee member which are included in the evidence review, they are part of a larger evidence base for this topic and being a co-author on them is unlikely to unduly influence decision making for this topic.
Professor Ranjit Manchanda	Topic Adviser	Direct non-financial professional and personal interest	Chief investigator on PROTECT-C trial. Additional Grant award from Yorkshire Cancer Research to QMUL for this study in April 2023	15/04/2023	10/05/2023	Ongoing	Specific. Declare and participate.  Rationale: This trial is ongoing and will not be finished before the guideline is published.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor Ranjit Manchanda	Topic Adviser	Direct non-financial professional and personal interest	Invited to join the NICE Quality Standards Advisory Committee as specialist member to develop the update to the NICE ovarian cancer quality standard	November 2023	14/11/2023	Ongoing	Specific. Declare and participate. Rationale: No further recommendations are being developed and therefore participation in the Quality Standard does not impact on this guideline.
Professor Glenn McCluggage	Committee member	Direct financial interest	Consultant Histopathologist at Belfast Health and Social Care Trust	01.08.1988	27/10/2022	Ongoing	Non-specific. Declare and participate. Rationale: Salaried employment in the NHS.
Professor Glenn McCluggage	Committee member	Direct financial interest	I do a minimal amount of reporting of private cases (on average approximately 2 hours per week). This is histopathology reporting and it is possible that a very occasional patient will have a familial ovarian cancer.	Ongoing for many years	09/02/2022	Ongoing	Non-specific. Declare and participate. Rationale: This private practice is not specifically related to ovarian cancer and the proportion of cases ovarian cancer and potential financial from this would be low.
Professor Glenn McCluggage	Committee member	Direct financial interest	I have had no direct payments from the commercial sector in the past year.	N/A	09/02/2022	N/A	Non-specific. Declare and participate. Rationale: No direct payments were received.
Professor Glenn McCluggage	Committee member	Direct non-financial professional and personal interests	Lead investigator on the Protector trial	2018	09/02/2022	Ongoing	Specific. Declare and participate, but to be reviewed when the relevant evidence is being presented.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
							Rationale: This trial was not published at the time of guideline development and therefore is not part of the evidence base.
Dr Kevin Monahan	Committee member	Direct financial interests	National health Service Consultant Gastroenterologist	2009	16/11/2022	Ongoing	Non-specific. Declare and participate. Rationale: Salaried employment in the NHS.
Dr Kevin Monahan	Committee member	Direct financial interests	NHS Genomic medical service Lynch syndrome project lead	2021	16/11/2022	Ongoing	Non-specific. Declare and participate. Rationale: Salaried employment in the NHS.
Dr Kevin Monahan	Committee member	Direct non-financial professional and personal interests	Medical Advisory Board: Bowel Cancer UK	2014	20/03/2022	Ongoing	Non-specific. Declare and participate. Rationale: This is non-specific to the scope of the guideline.
Dr Kevin Monahan	Committee member	Direct non-financial professional and personal interests	Lynch Syndrome UK	2014	20/03/2022	Ongoing	Specific. Declare and participate. Rationale: Even though Lynch syndrome is included in the scope of the guideline, it is only one of the syndromes that may be covered. There is no financial gain from this declaration and any decisions made by Lynch Syndrome UK are made on consensus of its members rather

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
							than according to members' personal opinions.
Dr Kevin Monahan	Committee member	Direct non-financial professional and personal interest	Lead for NHSE/GMSA Lynch syndrome project	2021	20/03/2022	Ongoing	Specific. Declare and participate. Rationale: Even though Lynch syndrome is not excluded from the scope it is only an example of all possible syndromes that may increase risk of ovarian cancer. The committee member's involvement in this project would therefore not influence the outcome of the discussion.
Dr Tracie Miles	Committee member	Direct financial interest	Associate Director of Nursing and Midwifery SWGMSA (NHS)	October 2021	24/10/2022	Ongoing	Non-specific. Declare and participate. Rationale: Salaried employment in the NHS.
Dr Tracie Miles	Committee member	Direct financial interest	Nurse Specialist to The Eve Appeal Gynaecology Cancer Research Charity	May 2016	24/10/2022	Ongoing	Non-specific. Declare and participate. Rationale: Salaried employment in a non-for profit sector.
Dr Tracie Miles	Committee member	Direct non-financial professional and personal interest	Support patient and clinician facing information on ovarian cancer testing with to include conferences and webinars with The Eve Appeal	2016	07/02/2022	Ongoing	Specific. Declare and participate. Rationale: This is a direct interest, but with no clear financial benefit to the person.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Tracie Miles	Committee member	Direct non-financial professional and personal interest	Invited to join the NICE Quality Standards Advisory Committee as specialist member to develop the update to the NICE ovarian cancer quality standard	November 2023	14/11/2023	Ongoing	Specific. Declare and participate. Rationale: No further recommendations are being developed and therefore participation in the Quality Standard does not impact on this guideline.
Dr Davina Moses	Committee member	Direct financial interest	Clinical Psychologist, Cancer Psychological Services, Barts Health Trust. This role includes work within the Familiar Cancer Clinic at Barts Health	January 2019	24/10/2022	Ongoing	Non-specific. Declare and participate. Rationale: Salaried employment in the NHS.
Dr Davina Moses	Committee member	Direct financial interest	Private practice; psychological therapy. Associate clinician at HelloSelf – unrelated to ovarian cancer	September 2017	08/02/2022	Ongoing	Non-specific. Declare and participate. Rationale: This interest is financial in the private health sector but it is non-specific to the scope of the guideline.
Dr Davina Moses	Committee member	Direct financial interest	Examiner fees for viva examining on Doctoral Programme of Clinical Psychology, University of East London	November 2020	08/02/2022	Ongoing	Non-specific. Declare and participate. Rationale: This could be a direct interest, but with no clear financial benefit for the committee member in relation to the scope of the guideline.
Dr Davina Moses	Committee member	Direct financial interest	Speaker fees from Janssen for panel discussion	October 2020	08/02/2022	October 2020	Non-specific. Declare and participate. Rationale: Interest no longer active and also over a year old.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Davina Moses	Committee member	Direct financial interest	Speaker fees from Janssen Pharmaceutical Companies of Johnson & Johnson for HME Roundtable Debate	January 2021	08/02/2022	January 2021	Non-specific. Declare and participate. Rationale: Interest no longer active and also over a year old.
Dr Davina Moses	Committee member	Direct financial interest	Speaker fees from Ipsen for panel discussion	December 2021	08/02/2022	December 2021	Non-specific. Declare and participate. Rationale: Ipsen does not produce medication that is relevant to the scope of the guideline.
Dr Davina Moses	Committee member	Direct non-financial professional and personal interest	As part of my clinical role at Barts Health Trust I may work with individuals referred to my service who are part of an ongoing trial, including the PROTECTOR Study. My role is not directly related to the trial or recruitment.	January 2019	08/02/2022	Ongoing	Non-specific. Declare and participate. Rationale: This is only indirectly related to the PROTECTOR trial and therefore does not constitute a conflict.
Mrs Fiona Robb	Committee member		Nothing to declare				N/A
Dr Adam Rosenthal	Committee member	Direct financial interest	Co-Director, Smart Medics (London) Ltd. Offering private gynaecology services to insured and fee-paying patients: This is on average 1 session per week in private sector at most. It includes ad hoc operating in evenings - max x2 lists per month. This is all declared on the NHS job plan and does not conflict with my NHS sessions. A small minority of my patients would be women at increased risk of ovarian cancer – this amounts to probably 5-10 risk-reducing salpingo oophorectomy procedures in the	2017	24/10/2022	Ongoing	Specific. Partial exclusion from surveillance topic area. Participate in discussion but excluded from decision-making on recommendation wording. Rationale: Private practice is provided on a sessional basis and the scope for potential benefit is small. Complete exclusion from the meeting would diminish the committee's access to

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
			private sector per year. There is also ROCA surveillance of probably approx 15 women undergoing this at any one time. Vast majority of the private practice is for completely unrelated issues - usually colposcopy for abnormal smears and investigation of gynaecological symptoms for example heavy menstrual bleeding or postmenopausal bleeding.				clinical expertise on matters under discussion.
Dr Adam Rosenthal	Committee member	Direct financial interest	Consultant Gynaecologist, University College London Hospitals NHS Foundation Trust, leading the familial gynaecological cancer prevention service.	2014	24/10/2022	Ongoing	Non-specific. Member's paid employment. Declare and participate. Rationale: Salaried employment in the NHS.
Dr Adam Rosenthal	Committee member	Direct financial interest	Co-Director, Smart Medics (London) Ltd. Offering private gynaecology services to insured and fee-paying patients. 4 hours a week, more limited in scope than his NHS practice	2017	06/02/2022	Ongoing	Non-specific. Declare and participate. Rationale: relatively limited private practice for general gynaecology rather than specifically related to ovarian cancer. Also, more limited rather than wider options provided in private practice compared to member's NHS practice.
Dr Adam Rosenthal	Committee member	Direct financial interest	Paid consultant, Everything Genetic Ltd. Advising the company about providing genetic testing in the private sector. Private gene testing (panel testing), has now been over a year ago and is not intending to do consultancy for this company again.	2017	06/02/2022	January 2021	Specific. Declare and participate. Rationale: Advising the company about providing genetic testing in the private sector. This has now been over a year

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
							ago and is not intending to do consultancy for this company again.
Dr Adam Rosenthal	Committee member	Direct financial interest	Paid consultant, Abcodia. Advising the company about providing ovarian cancer screening in the private sector.	2017	06/02/2022	June 2021	<p><u>Specific.</u></p> <p><u>At recruitment:</u> Declare and exclude from drafting recommendations on screening.</p> <p><u>Update July 2022:</u> Declare and participate.</p> <p>Rationale: Directly relevant and potentially with contact in future and potential for direct financial gain.</p> <p><u>Update rationale July 2022:</u> The committee member has last been consulted on this by the Abcodia company in June 2021 and has no longer an ongoing consultancy relationship with this company. This is because the potential to financially benefit has ceased. Therefore, the interest is no longer active.</p>
Dr Adam Rosenthal	Committee member	Direct non-financial professional and personal interest	Member of Board of Trustees of the Eve Appeal (a UK gynaecological cancer charity).	2021	06/02/2022	Ongoing	<p><u>Specific.</u></p> <p>Declare and participate.</p> <p>Rationale: This is a direct interest, but with no clear financial benefit to the person.</p>
Dr Adam Rosenthal	Committee member	Direct non-financial professional	Medical adviser to the Eve Appeal. I have worked with the Eve Appeal for 17 years and in 2018 I approached NICE with the	2004	06/02/2022	Ongoing	<p><u>Specific.</u></p> <p>Declare and participate.</p>



Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
		and personal interest	support of this charity and Dr. Eddie Morris, then Vice-President and now President of the RCOG, asking if NICE would consider commissioning a Familial Ovarian Cancer Guideline.				Rationale: This is a direct interest, but with no clear financial benefit to the person.
Dr Adam Rosenthal	Committee member	Direct non-financial professional and personal interest	Clinical Lead and first author on the UK Familial Ovarian Cancer Screening Study (UKFOCSS) phase 1 and 2; UK national trials of ovarian cancer surveillance in high-risk women. Publications from this trial are likely to be submitted as evidence to this committee.	2004	06/02/2022	2017	Specific.  Partial exclusion from surveillance topic area. Participate in discussion but excluded from decision-making on recommendation wording.  Rationale: Private practice is provided on a sessional basis and the scope for potential benefit is small. Complete exclusion from the meeting would diminish the committee's access to clinical expertise on matters under discussion.
Dr Adam Rosenthal	Committee member	Direct non-financial professional and personal interest	Chief Investigator, the Avoiding Late Diagnosis in Ovarian Cancer (ALDO) project; a pilot national ovarian cancer surveillance project for BRCA-carriers. Publications from this trial are likely to be submitted as evidence to this committee if they have been published prior to the guideline evidence cut-off date  Full reference: Philpott S, Raikou M, Manchanda R, Lockley M, Singh N, Scott M, Evans DG, Adlard J, Ahmed M, Edmondson R, Woodward ER. The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic	2018	06/02/2022	October 2022	Specific.  Partial exclusion from surveillance topic area. Participate in discussion but excluded from decision-making on recommendation wording.  Rationale: Private practice is provided on a sessional basis and the scope for potential benefit is small. Complete exclusion from the meeting would diminish the committee's access to clinical expertise on matters under discussion.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
			germline variants in BRCA1 and BRCA2. Journal of Medical Genetics. 2022 Oct 10.				
Dr Adam Rosenthal	Committee member	Direct non-financial professional and personal interest	British Gynaecological Cancer Society; I was asked to represent this specialist society at the initial scoping stakeholder meeting for this guideline.	2021	06/02/2022	Ongoing	Specific. Declare and participate. Rationale: This is a direct interest, but with no clear financial benefit to the person.
Dr Adam Rosenthal	Committee member	Direct financial interest	I was previously a paid consultant of Abcodia, advising the company about providing ovarian cancer screening in the private sector. Abcodia hold the license for the ROCA test. This test was used in the UKFOCSS trial and ALDO project (details in section 2 above). Evidence regarding this test is likely to be considered by the committee.	2018	06/02/2022	June 2021	Specific. Partial exclusion from surveillance topic area. Participate in discussion but excluded from decision-making on recommendation wording. Rationale: Private practice is provided on a sessional basis and the scope for potential benefit is small. Complete exclusion from the meeting would diminish the committee's access to clinical expertise on matters under discussion.
Dr Lucy Side	Committee member	Direct financial interest	Consultant in Clinical Genetics, University Hospitals Southampton (UHS)	August 2017	03/11/2022	Ongoing	Non-specific. Member's paid employment. Declare and participate. Rationale: Salaried employment in the NHS.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Lucy Side	Committee member	Direct financial interest	I undertake private practice (approximately 2 hours per week) at the Genetics Centre at 90 Sloane Street, London SW1X 9PQ in addition to my full-time NHS post.  Sees patients with familial cancer but not particularly ovarian cancer. There is also an aspect of research involved in this relating to service evaluation.	1 <sup>st</sup> January 2020	15/02/2022	Ongoing	Non-specific. Declare and participate.  Rationale: Salaried sessional employment in the private health sector. This is non-specific to the scope of the guideline.
Dr Lucy Side	Committee member	Direct financial interest	Invited speaker – Eli Lilly sponsored meeting “Hot Topics in Endocrinology”	19/05/2023	25/05/2023	19/05/2023	Non-specific. Declare and participate.  Rationale: This is not specific to the scope of the guideline.
Dr Lucy Side	Committee member	Direct non-financial professional and personal interest	PTEN Research Scientific Advisory Board Member	2017	15/02/2022	Ongoing	Specific. Declare and participate.  Rationale: This is a direct interest, but with no clear financial benefit to the person.
Dr Lucy Side	Committee member	Direct non-financial professional and personal interest	IMPACT Study Steering Group Member (Identification of Men with a genetic predisposition to Prostate Cancer: Targeted Screening Study) – based at the Institute of Cancer Research, London	2018	15/02/2022	Ongoing	Non-specific. Declare and participate.  Rationale: This is not directly related to the scope of the guideline.
Dr Lucy Side	Committee member	Direct non-financial professional and personal interest	90S Study Steering Group Member (evaluating the feasibility and acceptability of whole genome sequencing (WGS) as an additional screening tool to family history, lifestyle and environmental factors in a	2018	15/02/2022	Ongoing	Specific. Declare and participate.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
			private general practice in London) based at the Institute of Cancer Research, London				Rationale: This is a direct interest, but with no clear financial benefit to the person.
Dr Lucy Side	Committee member	Indirect financial interest	PI, PROTECTOR study, UHS	2020	03/11/2022	Ongoing	Specific. Declare and participate. Rationale: Even though directly related to the scope of the guideline, this is an indirect interest without any personal financial gain. The trial was not published during guideline development and did therefore not feature as evidence.
Dr Lucy Side	Committee member	Indirect financial interest	Co-PI, PROMISE 2015 Study, University College London	2010	03/11/2022	August 2017	Specific. Declare and participate. Rationale: Even though directly related to the scope of the guideline, this is an indirect interest without any personal financial gain and the study was not published during the development of the guideline.
Mrs Joanne Stanford	Lay member	Direct financial interest	Previous employment: Cancer Prevention officer at Ovarian Cancer Action. Role involves raising awareness of hereditary cancer, explaining guidelines and testing eligibility, discussing health situations with patients, writing submissions for NICE.  Ovarian Cancer Action is registered as a stakeholder in the creation of this guideline and I have attended a scoping meeting.	October 2016	07/02/2022	May 2022	Non-specific. Member's paid employment. Declare and participate. Rationale: Salaried employment in the not-for-profit sector.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Mrs Joanne Stanford	Lay member	Direct financial interest	Employed by Ovarian Cancer Action, who have made public their stance on the importance of genetic testing for ovarian cancer patients	October 2016 and October 2023	07/02/2022 and 07/11/2023	May 2022 and ongoing	Specific. Declare and participate. Rationale: This is a direct interest but there is no personal financial benefit associated from this role and being a committee member on the guideline.
Mrs Joanne Stanford	Lay member	Direct financial interest	Previously employed as Midlands Support Hub Coordinator at Ovacome, the ovarian cancer support charity. Role involves running support groups with patients, raising awareness of the disease, answering questions about genetic testing eligibility when they arise and discussing health situations with patients. My current role is not focused on hereditary cancer but general ovarian cancer support, however the charity does produce information about hereditary cancer and genetic testing.	May 2022	13/06/2022	October 2023	Specific. Declare and participate. Rationale: Whilst this was a paid role and directly related to the topic there was no financial gain from this that was related to the committee work.
Mrs Joanne Stanford	Lay member	Indirect financial interest	My employer (Ovarian Cancer Action) has received funding grants from multiple pharmaceutical companies to support various projects, including funding BRCA awareness posters and peer support webinars (with no input into content at any point). I have no direct input from these funders personally to influence my opinions.	October 2016	07/02/2022	May 2022	Specific. Declare and participate. Rationale: This is an indirect interest.
Mrs Joanne Stanford	Lay member	Indirect financial interest	Previous employer Ovacome has received funding grants from pharmaceutical companies to support projects, including	May 2022	13/06/2022	October 2023	Specific. Declare and participate. Rationale: This is an indirect interest.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
			funding BRCA awareness work. This was before my time at the charity.				
Mrs Joanne Stanford	Lay member	Direct financial interest	Current employment: Special Projects Manager at Ovarian Cancer Action. Role involves working on a variety of projects related to ovarian cancer, including hereditary cancer, explaining guidelines and testing eligibility, discussing health situations with patients, writing submissions for NICE and content for website.  Ovarian Cancer Action is registered as a stakeholder for the guideline.	October 2023	07.11.2023	Ongoing	Non-specific. Member's paid employment. Declare and participate. Rationale: This is the member's salaried employment in the charity sector.
Dr Britta Stordal	Committee member	Direct financial interest	Senior Lecturer Middlesex University – Primary Employment	2014	18/10/2022	Ongoing	Non-specific. Declare and participate. Rationale: Salaried employment in higher education (Middlesex University)
Dr Britta Stordal	Committee member	Direct financial interest	EU Research Executive Agency – Grant Review – Occasional Contract Work reviewing grants	2010	06/06/2022	Ongoing	Non-specific. Declare and participate. Rationale: Whilst this is a paid role there is no financial gain from this that is related to the committee work.
Dr Britta Stordal	Committee member	Direct non-financial professional and personal interest	Trustee – Breast Cancer UK  Cancer prevention charity, primarily focused on limiting the use of endocrine disrupting chemicals. The website provides information about BRCA1 and cancer risk.	May 2021	11/02/2022	Ongoing	Non-specific. Declare and participate. Rationale: This is a direct interest, but with no clear financial benefit to the person.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Britta Stordal	Committee member	Direct non-financial professional and personal interest	NICE Technology Appraisal Committee	November 2022	12/12/2022	Ongoing	Non-specific. Declare and participate. Rationale: This Technology Appraisal is not directly related to the scope of the guideline.
Dr Britta Stordal	Committee member	Direct non-financial professional and personal interest	Vice Chair and Head of Science and Public Affairs Committee Breast Cancer UK	2021	06/06/2023	Ongoing	Non-specific. Declare and participate. Rationale: This is not specific to the scope of the guideline.
Dr Britta Stordal	Committee member	Direct non-financial professional and personal interest	Lay Member of Clinical Oncology Academic Committee – Royal College of Radiologists	2022	06/06/2023	Ongoing	Non-specific. Declare and participate. Rationale: This is not specific to the scope of the guideline.
Dr Britta Stordal	Committee member	Direct non-financial professional and personal interest	NICE - Specialist committee member for Diagnostics Advisory Committee - Tumour profiling tests to guide adjuvant chemotherapy decisions in lymph node-positive early breast cancer	2023	06/06/2023	Ongoing	Non-specific. Declare and participate. Rationale: This is not specific to the scope of the guideline.
Dr Britta Stordal	Committee member	Direct non-financial professional and personal interest	Lay Member of UK Systemic Anti-Cancer Therapy (SACT) Board	2023	06/06/2023	Ongoing	Non-specific. Declare and participate. Rationale: This is not specific to the scope of the guideline.
Dr Vishakha Tripathi	Committee member	Direct financial interest	Consultant Genetic Counsellor, Guy's & St Thomas' NHS Foundation Trust	01/05/2015	31/10/2022	Ongoing	Non-specific. Member's paid employment.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
							Declare and participate. Rationale: Salaried employment in the NHS.
Dr Vishakha Tripathi	Committee member	Direct financial interest	Director of DNA_CONNECT	01/01/2019	21/02/2022	Ongoing	Specific. Declare and participate. Rationale: This has been set up to cover private practice but member has not seen any people in their private practice.
Dr Vishakha Tripathi	Committee member	Direct financial interest	Practicing privileges at KEVII, HCA	01/11/2021	21/02/2022	Ongoing	Non-specific. Declare and participate. Rationale: This relates to private practice. Member has not yet seen any patients but in future it might involve ovarian cancer. There are no plans to practice privately in a big way (not anticipating more than 2 hours a week).
Dr Vishakha Tripathi	Committee member	Direct financial interest	Consulting for Halo	01/11/2021	21/02/2022	01/11/2021	Non-specific. Declare and participate. Rationale: This was a one-time activity.
Dr Vishakha Tripathi	Committee member	Direct non-financial professional and personal interest	Member of clinical genetics CRG	2019	21/02/2022	Ongoing	Non-specific. Declare and participate. Rationale: She is a member rather than the chair of a CRG and decisions are made by consensus.



Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Vishakha Tripathi	Committee member	Direct non-financial professional and personal interest	Board member, GCRB	2015	21/02/2022	Ongoing	Non-specific. Declare and participate. Rationale: As a board member, decisions are made by consensus rather than being a reflection of each members personal opinion.
Dr Vishakha Tripathi	Committee member	Direct non-financial professional and personal interest	Professional member, AHCS	2019	21/02/2022	Ongoing	Non-specific. Declare and participate. Rationale: As a board member, decisions are made by consensus rather than being a reflection of each members personal opinion.
Dr Vishakha Tripathi	Committee member	Direct non-financial professional and personal interest	External examiner to MSc Genetic & Genomic Counselling, Cardiff University	01/10/2022	31/10/2022	Ongoing	Non-specific. Declare and participate. Rationale: This declaration is not specific to the scope of the guideline.
Dr Vishakha Tripathi	Committee member	Direct non-financial professional and personal interest	Gaba, F.; Blyuss, O.; Chandrasekaran, D.; Osman, M.; Goyal, S.; Gan, C.; Izatt, L.; Tripathi, V.; Esteban, I.; McNicol, L.; Ragupathy, K.; Crawford, R.; Evans, D.G.; Legood, R.; Menon, U.; Manchanda, R. Attitudes towards risk-reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study. BJOG: An International Journal of Obstetrics and Gynaecology; 2021; vol. 128 (no. 4); 714-726	2021	24/03/2023	Ongoing	Specific. Declare and participate. Rationale: This publication was included in evidence report N. This is only one part of a considerable evidence base for this topic and being a co-author is unlikely to unduly influence decision making for this topic.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Vishakha Tripathi	Committee member	Direct non-financial professional and personal interest	Gaba, F; Blyuss, O; Chandrasekaran, D; Osman, M; Goyal, S; Gan, C; Izatt, L; Tripathi, V; Esteban, I; McNicol, L; Ragupathy, K; Crawford, R; Evans, D G; Legood, R; Menon, U; Manchanda, R. Attitudes towards risk-reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study. BJOG: an international journal of obstetrics and gynaecology 128(4): 714-726, 2021	2021	12/05/2023	Ongoing	Specific. Declare and participate. Rationale: This publication was included in evidence report P. This is only one part of a considerable evidence base for this topic and being a co-author is unlikely to unduly influence decision making for this topic.
Professor Alistair McGuire	Expert witness	Indirect financial interest	Research payment to LSE to undertake academic work on economic evaluation	September 2020	10/01/2023	September 2022	Specific. Declare and participate. Rationale: This was an economic evaluation for the topic that we invited the expert witness to talk about. As an expert witness he was not part of the decision making.
Ms Xia Wei	Expert witness		No interests to declare		21/02/2023		N/A
Dr Rosa Legood	Expert witness		No interests to declare		02/05/2023		N/A